Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment.

Published on Jan 1, 2015in European Addiction Research2.269
· DOI :10.1159/000363232
Michael Soyka62
Estimated H-index: 62
(LMU: Ludwig Maximilian University of Munich)
Maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Clinical studies indicate that about a third of patients in opioid maintenance therapy show increased alcohol consumption and alcohol use disorders. Comorbid alcohol use disorders have been identified as a risk factor for clinical outcome and can cause poor physical and mental health, including liver disorders, noncompliance, social deterioration and increased mortality risk. The effects of opioid maintenance therapy on alcohol consumption are controversial and no clear pattern has emerged. Most studies have not found a change in alcohol use after initiation of maintenance therapy. Methadone and buprenorphine appear to carry little risk of liver toxicity, but further research on this topic is required. Recent data indicate that brief intervention strategies may help reduce alcohol intake, but the existing evidence is still limited. This review discusses further clinical implications of alcohol use disorders in opioid dependence.
Figures & Tables
📖 Papers frequently viewed together
68 Citations
92 Citations
11 Citations
#1Jan KlimasH-Index: 15
#2Helen Tobin (UCD: University College Dublin)H-Index: 7
Last. Walter Cullen (UCD: University College Dublin)H-Index: 24
view all 10 authors...
Cochrane Training Fellowship awarded to the lead author by Health Research Board of Ireland (Grant No. CTF-2010-9)
66 CitationsSource
#1Michael SoykaH-Index: 62
#2Markus Backmund (Praxis)H-Index: 24
Last. Sabine ApeltH-Index: 5
view all 4 authors...
Background Some case series mention possible liver toxicity in opioid-dependent patients under buprenorphine treatment. Methods This 12-month prospective observational follow-up study in opioid-dependent patients under buprenorphine–naloxone treatment assessed outcome and safety issues. At baseline, 337 eligible datasets were available; 181 patients completed the 12-month study. Liver enzymes were tested at baseline and after 12, 24, and 52 weeks' treatment. Results One to two percent of patient...
8 CitationsSource
#1Gregory M. Lucas (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 47
#2Alicia Young (Fred Hutchinson Cancer Research Center)H-Index: 3
Last. David M. Burns (NIH: National Institutes of Health)H-Index: 6
view all 14 authors...
Abstract Background Buprenorphine/naloxone (BUP/NX), an effective treatment for opioid dependence, has been implicated in hepatic toxicity. However, as persons taking BUP/NX have multiple hepatic risk factors, comparative data are needed to quantify the risk of hepatoxicity with BUP/NX. Methods We compared rates of alanine aminotransferase (ALT) elevation ≥ grade 3 (ALT ≥ 5.1 times the upper limit of normal) and graded bilirubin elevations in HIV-negative opioid injectors randomized to long-term...
5 CitationsSource
#1Scott Veldhuizen (CAMH: Centre for Addiction and Mental Health)H-Index: 33
#2Russell C. Callaghan (UNBC: University of Northern British Columbia)H-Index: 22
Abstract Purpose Although numerous studies have reported on all-cause mortality among opioid users, few have provided estimates for specific causes of death. We report all-cause and cause-specific mortalities for a large cohort of individuals with a history of opioid-related disorders. Methods We used administrative data on people discharged from California hospitals between 1990 and 2005 with diagnoses of opioid dependence, abuse, poisoning, or withdrawal. We calculated crude and standardized c...
15 CitationsSource
#1Jan Klimas (UCD: University College Dublin)H-Index: 15
#2Catherine Anne Field (UCD: University College Dublin)H-Index: 9
Last. Colum P. Dunne (UL: University of Limerick)H-Index: 32
view all 9 authors...
3 CitationsSource
#1Michael Soyka (LMU: Ludwig Maximilian University of Munich)H-Index: 62
To date, few pharmacotherapies have been established for the treatment of alcoholism. There is a plethora of research concerning the involvement of the opioid-endorphin system in mediating the reinforcing effects of alcohol. The opioid antagonist naltrexone has been found to be effective in alcohol treatment. In addition, the mu-opioid antagonist and partial kappa agonist nalmefene was recently approved by the European Medicines Agency for the treatment of alcoholism. The relevant studies follow...
24 CitationsSource
#1Sheng-Chang WangH-Index: 16
#2Hsiao-Hui Tsou (PRC: China Medical University (PRC))H-Index: 1
Last. Yu-Li LiuH-Index: 14
view all 16 authors...
AbstractMethadone is a synthetic opioid that binds to the κ-opioid receptor with a low affinity. This study tested the hypotheses that the genetic polymorphisms in the κ-opioid receptor 1 (OPRK1) gene region are associated with methadone treatment responses in a Taiwan methadone maintenance treatmen
21 CitationsSource
#1Richard S. Schottenfeld (Yale University)H-Index: 56
#2Marek C. Chawarski (Yale University)H-Index: 28
Last. Thomas R. Kosten (Michael E. DeBakey Veterans Affairs Medical Center in Houston)H-Index: 108
view all 6 authors...
Abstract Background Disulfiram may be efficacious for treating cocaine dependence or abuse, possibly through inhibiting dopamine β-hydroxylase (DβH). Consequently, this randomized, placebo-controlled clinical trial of disulfiram during buprenorphine maintenance treatment evaluated the study hypothesis that disulfiram is superior to placebo and explored whether disulfiram response is greatest for participants with a single nucleotide polymorphism coding for genetically low DβH (T-allele carriers)...
17 CitationsSource
#1Richard P. Mattick (NDARC: National Drug and Alcohol Research Centre)H-Index: 69
#2Courtney Breen (UNSW: University of New South Wales)H-Index: 21
Last. Marina DavoliH-Index: 52
view all 4 authors...
Methadone is widely used as a replacement for illicit opioid use such as heroin in medically-supported opioid substitution maintenance programmes. Two other drugs have been used to help reduce illicit opioid use, specifically buprenorphine and LAAM (levo-alpha-acetylmethadol). LAAM is not used in current clinical practice. Buprenorphine is currently used and can reduce illicit opioid use compared with placebo, although it is less effective than methadone. Buprenorphine is an opioid drug that is ...
1,226 CitationsSource
#1Michael J. Ferri (Vandy: Vanderbilt University)H-Index: 2
#2Alistair James Reid Finlayson (Vandy: Vanderbilt University)H-Index: 3
Last. Peter R. Martin (Vandy: Vanderbilt University)H-Index: 52
view all 4 authors...
Background and Objectives Despite the dramatic increase in the use of buprenorphine for the treatment of opioid dependence, clinical outcomes of this treatment approach continue to need evaluation. This study examines factors associated with relapse and retention during buprenorphine treatment in a sample of opioid dependent outpatients. Methods In a retrospective chart review of 62 patients with opioid dependence, relapse was determined by self-report, urine toxicology screens, and by checking ...
27 CitationsSource
Cited By43
#1Jan Klimas (UBC: University of British Columbia)H-Index: 15
#2Wing Yin Mok (UBC: University of British Columbia)
Last. M-J Milloy (UBC: University of British Columbia)H-Index: 16
view all 0 authors...
Background: While preliminary evidence has begun to document intentional use of one substance to reduce the use of another, the phenomenon of drug substitution among people who use illicit opioids ...
#1Carrie M. Mintz (WashU: Washington University in St. Louis)H-Index: 2
#2Ned Presnall (UW: University of Washington)H-Index: 5
Last. Richard A. Grucza (SLU: Saint Louis University)H-Index: 55
view all 0 authors...
BACKGROUND AND AIMS Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied. We identified whether co-occurring AUD was associated with OUD treatment type, compared associations between treatment type and six-month treatment retention and determined whether co-occurring AUD moderated these relationships. METHODS We used an observational cohort study design to analyze insurance claims data from 2011 to 2016 from persons aged 12-64 with an opioid abuse o...
#1Martha CanfieldH-Index: 5
#2Sam NortonH-Index: 36
Last. Gail GilchristH-Index: 21
view all 4 authors...
Abstract Background Many women receiving substance use treatment services are mothers. Despite this, research has not proved whether substance use treatment services are addressing the specific needs of mothers. This study explored differences in sociodemographic, psychological, patterns of substance use, and treatment characteristics between mothers and women without children, and between mothers whose children were in alternative care. Method The study extracted data from electronic patient re...
#1Kevin Y. Xu (WashU: Washington University in St. Louis)H-Index: 3
#2Ned Presnall (WashU: Washington University in St. Louis)H-Index: 5
Last. Richard A. Grucza (SLU: Saint Louis University)H-Index: 55
view all 7 authors...
Importance: Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied and undertreated. It is unknown whether the use of medications to treat OUD is associated with reduced risk of alcohol-related morbidity. Objective: To determine whether the use of OUD medications is associated with decreased risk for alcohol-related falls, injuries, and poisonings in persons with OUD with and without co-occurring AUD. Design, Setting, and Participants: This recurrent-...
#1Nicola R. Jones (NDARC: National Drug and Alcohol Research Centre)H-Index: 4
#2Matthew Hickman (UoB: University of Bristol)H-Index: 90
Last. Louisa Degenhardt (NDARC: National Drug and Alcohol Research Centre)H-Index: 138
view all 9 authors...
Abstract Background To examine, among a cohort of opioid dependent people with a history of opioid agonist treatment (OAT), the frequency and incidence rates of non-fatal overdose (NFOD) hospital separations over time, by age and sex. Methods Retrospective cohort study of people with a history of OAT using state-wide linked New South Wales (NSW) data. The incidence of NFOD hospital separations involving an opioid, sedative, stimulant or alcohol was defined according to the singular or combinatio...
#1Lynn T. Singer (Case Western Reserve University)H-Index: 61
#2Christina D. Chambers (UCSD: University of California, San Diego)H-Index: 60
Last. Julie A. Kable (Emory University)H-Index: 23
view all 4 authors...
Current efforts to design research on developmental effects of prenatal opioid exposure can benefit from knowledge gained from 50 years of studies of fetal alcohol and prenatal drug exposures such as cocaine. Scientific advances in neurobiology, developmental psychopathology, infant assessments, genetics, and imaging support the principles of developmental neurotoxicology that guide research in prenatal exposures. Important to research design is accurate assessment of amount, frequency, and timi...
#1Mohammad Rifat Haider (OU: Ohio University)H-Index: 9
#2Monique J. Brown (USC: University of South Carolina)H-Index: 12
Last. Xiaoming Li (USC: University of South Carolina)H-Index: 102
view all 6 authors...
BACKGROUND The United States (US) has experienced an opioid epidemic over the last two decades. Drug overdose deaths increased by 21% from 2015 to 2016, with two-thirds of these deaths attributed to opioid use disorder (OUD). This study assessed the psycho-social correlates associated with OUD over 2015-2018 in the US. Methods: This study used data collected from 171,766 (weighted = 245,838,163) eligible non-institutionalized US adults in the pooled National Survey on Drug Use and Health from 20...
2 CitationsSource
#1Polly Radcliffe ('KCL': King's College London)H-Index: 13
#2Martha Canfield ('KCL': King's College London)H-Index: 5
Last. Gail Gilchrist (University of Melbourne)H-Index: 21
view all 7 authors...
AbstractIntroduction: Although alcohol is widely used concurrently with illicit drugs, the role of alcohol in recovery from and relapse to drug use is under-researched. This study investigates drin...
2 CitationsSource
#1Huiru Dong (UBC: University of British Columbia)H-Index: 15
#2Kanna Hayashi (SFU: Simon Fraser University)H-Index: 24
Last. Thomas Kerr (UBC: University of British Columbia)H-Index: 96
view all 8 authors...
Abstract Background Although previous studies have shown that opioid agonist therapy (OAT) is linked to reductions in illicit opioid use, less is known about how OAT impacts the use of other psychoactive substances. We aimed to examine the changes in use of different substances by comparing patterns before and after initiating OAT. Methods Data for this study was derived from three ongoing prospective cohorts involving people who use drugs in Vancouver, Canada from 1996 to 2018. We assessed use ...
2 CitationsSource
#1Chirag Nagpal (CMU: Carnegie Mellon University)H-Index: 3
#2Dennis Wei (IBM)H-Index: 18
Last. Kush R. Varshney (IBM)H-Index: 23
view all 7 authors...
The dearth of prescribing guidelines for physicians is one key driver of the current opioid epidemic in the United States. In this work, we analyze medical and pharmaceutical claims data to draw insights on characteristics of patients who are more prone to adverse outcomes after an initial synthetic opioid prescription. Toward this end, we propose a generative model that allows discovery from observational data of subgroups that demonstrate an enhanced or diminished causal effect due to treatmen...
1 CitationsSource